Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 08, 2005. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 1,700,000 ordinary shares of 25 pence each.
- Purchase Price: 1,438.32 pence per share.
- Treasury Holdings: 133,558,000 shares held in Treasury following the transaction.
- Shares in Issue: 5,829,168,013 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares due to the open market purchase of 1,700,000 shares on December 08, 2005. This action was executed under authority granted by shareholders at the Annual General Meeting on May 25, 2005.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities in any jurisdiction.
Investor Verification Points
- Verify the total cost of the repurchase by multiplying the 1,700,000 shares by the 1,438.32 pence price.
- Confirm the updated total share capital structure (5,829,168,013 issued shares plus 133,558,000 treasury shares).
- Review the May 25, 2005 Annual General Meeting minutes to confirm the scope of the share buyback authority utilized.